High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)
St. Anna Kinderkrebsforschung
3,300 participants
Feb 1, 2002
INTERVENTIONAL
Conditions
Summary
This is a randomized study of the European SIOP Neuroblastoma Group (SIOPEN) in high-risk neuroblastoma (stages 2, 3, 4 and 4s MYCN-amplified neuroblastoma, stage 4 MYCN non amplified \> 12 months at diagnosis). The protocol consists of a rapid, dose intensive induction chemotherapy, peripheral blood stem cell harvest, attempted complete excision of the primary tumour, myeloablative therapy followed by peripheral blood stem cell rescue, radiotherapy to the site of the primary tumour and immunotherapy (R4 randomization - isotretinoin and ch14.18/CHO (Dinutuximab beta, Qarziba ®).), with or without s.c. aldesleukin (IL-2)). Patients diagnosed after the closure of R3 randomization will not be R4 randomized. For these patients the use of ch14.18/CHO antibody is recommended without scIL-2 as continuous infusion as standard of care outside of controlled trials. ch14.18/CHO received marketing authorization by EMA in May 2017 (Qarziba ®). In the induction phase, all patients receive Rapid COJEC following the result of the R3 randomization which was closed on June 8th, 2017 after inclusion of 630 patients as planned. Following induction treatment peripheral blood stem cell harvest (PBSCH) is performed and complete excision of the primary tumour will be attempted. Patients with an inadequate metastatic response to allow BuMel MAT followed by PBSCR at the end of induction should receive 2 TVD (Topotecan, Vincristine, Doxorubicin) cycles. After Rapid COJEC induction, localized patients will proceed to consolidation. Patients aged 12-18 months at diagnosis, with stage 4 neuroblastoma, no MYCN amplification and without segmental chromosomal alterations (SCAs) are thought to have a good prognosis and will stop treatment after induction therapy and surgery to the primary tumour. Consolidation consists of BuMel MAT based on the results of the R1 randomization followed by peripheral blood stem cell rescue (PBSCR) and radiotherapy to the site of the primary tumour. The R2 immunotherapy randomization using ch14.18/CHO as 8 hour infusion on 5 consecutive days ( total dose (100mg/m²) with or without aldesleukin (IL-2) alternated with isotretinoin (13-cis-RA) is closed. The amended R4 immunotherapy randomization using ch14.18/CHO as continuous infusion (total dose 100mg/m² over 10 days) with or without aldesleukin (IL-2) alternated with isotretinoin (13-cis-RA) has accrued according to plan with results pending awaiting data maturity and DMC approval.
Eligibility
Inclusion Criteria13
- • Established diagnosis of neuroblastoma according to the International Neuroblastoma Staging System (INSS).
- Age below 21 years.
- High risk neuroblastoma defined as either:
- INSS stage 2, 3, 4, and 4s with MYCN amplification, or
- INSS stage 4 without MYCN amplification aged \> 12 months at diagnosis
- Patients who have received no previous chemotherapy except for one cycle of etoposide and carboplatin (VP16/Carbo). In this situation patients will receive Rapid COJEC induction and the first Rapid COJEC cycle may be replaced by the first cycle VP16/Carbo (etoposide / carboplatin).
- Written informed consent, including agreement of parents or legal guardian for minors, to enter a randomised study if the criteria for randomisation are met.
- Tumour cell material available for determination of biological prognostic factors.
- Females of childbearing potential must have a negative pregnancy test. Patients of childbearing potential must agree to use an effective birth control method. Female patients who are lactating must agree to stop breast-feeding.
- Registration of all eligibility criteria with the data centre within 6 weeks from diagnosis.
- Provisional follow up of 5 years.
- National and local ethical committee approval.
- \-
Interventions
Cyclophosphamid is given during Induction Treatment (both R3 randomisation arms)
given during Rapid COJEC and modified N7 therapy
Aldesleukin is given during MRD Treatment for patients randomised to the arm with IL-2
ch14.18/CHO antibody is given during MRD treatment
Carboplatin is given during induction Treatment (R3 randomisation: Rapid COJEC arm)
Etoposide is given during Induction Treatment (both R3 randomisation arms)
Cisplatin is given during Induction Treatment (both R3 randomisation arms)
Doxorubicin is given during Induction Treatment (R3 arm modified N7)
G-CSF is given during Induction Treatment
In case i.v. busulfan is not available, the use of oral busulfan is permitted, although not recommended.
Melphalan is given during MAT treatment
Locations(126)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT01704716